Abeona Therapeutics Inc Propriété du management
Quel est le Propriété du management de Abeona Therapeutics Inc?
Le Propriété du management de Abeona Therapeutics Inc est 11.37%
Quelle est la définition de Propriété du management?
La propriété d'un initié est calculée en divisant le nombre total d'actions possédées par des initiés (actionnaires détenant plus de 5% de la société ou un dirigeant ou un administrateur de la société) par le nombre total d'actions en circulation.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Propriété du management des entreprises dans Health Care secteur sur NASDAQ par rapport à Abeona Therapeutics Inc
Que fait Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Entreprises avec propriété du management similaire à Abeona Therapeutics Inc
- Ramaco Resources Inc a Propriété du management de 11.36%
- QMC Quantum Minerals Corp a Propriété du management de 11.36%
- Catalyst Biosciences Inc a Propriété du management de 11.36%
- Palantir Technologies a Propriété du management de 11.36%
- Zenith a Propriété du management de 11.37%
- Aptitude Software plc a Propriété du management de 11.37%
- Abeona Therapeutics Inc a Propriété du management de 11.37%
- Life360 a Propriété du management de 11.38%
- Dalata Hotel plc a Propriété du management de 11.38%
- Roth CH Acquisition I Co a Propriété du management de 11.38%
- Copper Lake Resources a Propriété du management de 11.38%
- Copper Lake Resources a Propriété du management de 11.38%
- SBI a Propriété du management de 11.39%